Like it or not, electronic medical/health records (EMR/EHR) are here to stay. As the healthcare world continues to move away from fee-for-service and toward value-based medicine, there is an increasing need to accumulate historical data regarding patient outcomes in order to individualize patient management, treatment, and develop best practices. But as innovative health systems develop and implement programs to take advantage of the reams of data available to them, it becomes clear that there are crucial elements that must be considered.
As part of the Patient Protection and Affordable Care Act (ACA), the Hospital-Acquired Condition Reduction Program (HACRP) was established to incentivize hospitals to reduce the number of HAC’s per year (Source:www.cms.gov). HAC’s differ slightly from hospital-acquired infections (HAI’s) although both designations fall under the regulations set forth by the HACRP.
- HAI’s: infections patients may contract while under treatment in a healthcare facility (urinary tract infections, sepsis, etc).
- HAC’s: any other situation or condition that may occur (including medication errors, pressure sores, falls).
Spinal muscular atrophy (SMA) is a genetic disorder characterized by loss of motor neurons, leading to weakness and wasting of muscles used for activities such as crawling, walking, sitting up, and controlling head movement. In severe cases of SMA, the muscles used for breathing and swallowing are affected. This devastating disorder affects approximately 1 in 10,000 births and is the most common genetic cause of infant mortality. SMA is caused by deletions or mutations in a gene that leads to a deficiency of survival motor neuron (SMN) protein; this protein is critical for the maintenance of motor neurons. The severity of SMA is directly related to the amount of SMN protein.
The Neptune Waste Management Systems are used in operating room (OR) suites and surgical facilities to collect and dispose of surgical fluid waste. Some models also remove smoke generated at surgical sites by electrocautery or laser devices. In 2012, the manufacturer of these systems issued a voluntary class I recall. The Food and Drug Administration (FDA) defines class I recalls as those issued in situations in which there is a reasonable probability that the use of or exposure to a product will cause serious adverse health consequences or death.
2016 marked a banner year for our company. We are humbled by the loyalty of our ever-expanding client roster. At the same time, we take great pride in what we’ve accomplished over the last 12 months and we’d like to share some of those endeavors with you here. If you’re new to Hayes, or not yet a member, we invite you to view just a sample of the innovation and growth we’ve experienced as an indication of things to come.
So without further ado…
We’ve had recent questions regarding the Food and Drug Administration (FDA) approval process for new medical devices, so we felt it was time to revisit the topic. We realize that as both physicians and providers, the pressure can be great when both patients and clients come to you wanting information about the latest device reported on the news or Internet. The following is designed to give you an overview of the process to better inform those inevitable discussions.
Documented evidence of the use of honey for medicinal purposes has existed for centuries across continents and cultures. As is so often the case, what’s old is new again, and honey has seen a resurgence as a treatment, specifically as a topical ointment to aid in wound healing. Because of its antimicrobial properties, honey is often used when treatment with antibiotics and antiseptics have failed. The honey produced by the Manuka (species Leptospermum scoparium) flower of New Zealand has been shown to be one of the most powerful in this regard.
As 2016 draws to a close, we here are keeping our eyes fixed on the future for you. Increasingly healthcare-savvy patients want their providers to be up to date on the latest health technology advances, no matter what their stage in the FDA approval process. And while both patients and physicians may want these new drugs, procedures, or devices, payers may be equally unaware of the safety, efficacy, or patient appropriateness of the technologies they’re being asked to cover, particularly when they’re new to market and the peer-reviewed, published evidence is scarce.
You can’t get away from the word “value” in today’s healthcare environment. It’s in practically every headline of every blog, whitepaper, and email blast. From value-analysis teams to value-based medicine and purchasing, the word has become so commonplace, it risks losing its own value. With the continued shift away from fee-for-service medicine and toward pay-for-performance, we’ll need to embrace value as not only part of our vocabulary, but as a guide for our business practices. Along those lines, I’d like to take the opportunity this week to tell you about our business values; about how they make us the obvious choice for your health technology assessments; and about how our adherence to those values cost us $100,000.
WBUR’s “Here and Now” this week featured an article regarding the use of immunotherapies to decrease allergic reactions, specifically to peanuts.
Unless you’ve been living in a cave, you’re well aware of the significant health risks peanut allergies present to individuals. Symptoms run the spectrum from a runny nose and throat itchiness to full-blown anaphylaxis, which includes constriction of the airways, a severe drop in blood pressure (shock), and loss of consciousness. While the most common cause of a reaction is eating peanuts or food that contains them, they can also be triggered by skin contact, cross-contamination during food handling, and even inhalation of dusts or aerosols containing peanuts (Source: Mayoclinic.org). An allergic response to peanuts can occur in just minutes.